Akorn has again been pulled up by the FDA for deficiencies at its US manufacturing plant in Decatur, Illinois, concerning aseptic practices and cleaning procedures. Last year, the firm was issued a Form 483 inspection report for the site; now, it has been struck with an FDA warning letter.
Akorn has suffered another blow at its US sterile manufacturing plant in Decatur, Illinois, receiving a warning letter from the US Food and Drug Administration (FDA) for the facility, after it was last year hit with a ‘Form 483’ inspection report.
Following an audit at the Decatur plant from 9 April to 16 May 2018, the agency issued a warning letter...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
